SCHEMBL717339

SCHEMBL717339

CCOC(=O)c1sc2cnccc2c1C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.53
HTT P42858 3/20 0.53
HPGD P15428 3/20 0.53
KDM4E B2RXH2 3/20 0.53
GAA P10253 2/20 0.53
GLA P06280 1/20 0.53
CASP1 P29466 1/20 0.53
CASP7 P55210 1/20 0.53
NCOA1 Q15788 1/20 0.53
HSD17B10 Q99714 1/20 0.53
RCE1 Q9Y256 1/20 0.53
NCOA3 Q9Y6Q9 1/20 0.53
RPS6KB1 P23443 1/20 0.53
CDK2 P24941 1/20 0.53
MAPKAPK2 P49137 1/20 0.53
GSK3B P49841 1/20 0.53
RPS6KA3 P51812 1/20 0.53
CDC7 O00311 10/20 0.49
DBF4 Q9UBU7 10/20 0.49
MEN1 O00255 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL716897 0.89 CDC7 (0.49) ALDH1A1HTTHPGDKDM4EGAA
SCHEMBL31750868 0.89 CDC7 (0.49) ALDH1A1HTTHPGDKDM4EGAA
SCHEMBL1218547 0.87 KDM4E (0.52) ALDH1A1HTTHPGDKDM4EGAA
SCHEMBL30555073 0.87 KDM4E (0.52) ALDH1A1HTTHPGDKDM4EGAA
SCHEMBL24091065 0.87 KDM4E (0.52) ALDH1A1HTTHPGDKDM4EGAA
SCHEMBL17148975 0.86 ALDH1A1 (0.51) ALDH1A1HTTHPGDKDM4EGAA
SCHEMBL4723975 0.86 KDM4E (0.73) ALDH1A1HTTHPGDKDM4EGAA
SCHEMBL30338198 0.86 ALDH1A1 (0.51) ALDH1A1HTTHPGDKDM4EGAA
SCHEMBL1813746 0.85 ALDH1A1 (0.72) ALDH1A1HTTHPGDKDM4EGAA
SCHEMBL21874477 0.85 ALDH1A1 (0.53) ALDH1A1HTTHPGDKDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP ALDH1A1 504/4885HTT 1337/4885HPGD 486/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP ALDH1A1 504/4885HTT 1337/4885HPGD 486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.